Attached files
| file | filename |
|---|---|
| S-1/A - S-1/A (AMENDMENT NO. 1) - Oncotelic Therapeutics, Inc. | d579993ds1a.htm |
| EX-5.1 - EX-5.1 - Oncotelic Therapeutics, Inc. | d579993dex51.htm |
| EX-4.8 - EX-4.8 - Oncotelic Therapeutics, Inc. | d579993dex48.htm |
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We consent to the reference to our firm under the caption “Experts” in Amendment No. 1 to the Registration Statement (Form S-1 No. 333-190464) and related Prospectus of OXiGENE for the registration of shares of common stock, and to the incorporation by reference therein of our report dated March 15, 2013, with respect to the financial statements of OXiGENE, Inc., included in its Annual Report (Form 10-K) for the year ended December 31, 2012, filed with the Securities and Exchange Commission.
/s/ Ernst & Young LLP
Redwood City, California
August 28, 2013